Regulations and compliance · Practical guide

Annex 1: monitoring data and data integrity

Annex 1 connects monitoring data to the contamination control strategy for sterile manufacture. Each measurement needs an identifiable location, time and process. Acknowledging an alarm leaves the investigation and product assessment open. Trace the electronic evidence from monitoring point to action and establish what an individual reading can support.

Table of contents

At a glance

What role do electronic monitoring data play in a sterile manufacturing contamination control strategy?

Electronic monitoring data help assess whether sterile manufacturing controls remain effective. Link readings to location, time, method and process context. Annex 1 distinguishes alert and action findings and calls for appropriate assessment or investigation. Monitoring alone does not assure sterility. Acknowledging an alarm does not establish its cause or address possible product impact, including the period between measurement and reporting.

  • Monitoring is assessed as part of the overall contamination control strategy.
  • Maintain separate tracking of technical status notification and professional assessment decision.
  • Link time, assignment, and potential product impacts in a traceable and verifiable manner.

1. Define monitoring purpose and manufacturing scope

The article covers sterile manufacture of human medicines under EU GMP Annex 1. The August 2022 revision has applied in full since 25 August 2024, including point 8.123, which took effect later than the other provisions. Certain principles may also be used in selected non-sterile areas. The scope section calls for the selection and its implementation to be documented.

First, identify which contamination or process condition is being monitored and the decision that the data supports. Environmental monitoring, personal monitoring, total particle counting, or other relevant process parameters are not interchangeable. For example, a temperature profile alone does not substitute for a microbiological assessment. The specific methods and limits must align with the manufacturing process and the monitoring program.

Sources: [1] [2]

2. Assess data within the contamination control strategy

The Contamination Control Strategy (CCS) integrates architectural, technical, organizational, and procedural controls. Annex 1 emphasizes that monitoring or testing alone does not ensure sterility. Individual monitoring elements have limited analytical value; collectively, they support the evaluation of design, validation, and operation.

For electronic data: a continuous data stream may be important, but it does not prove that all required controls have been performed. Conversely, an out-of-range value must not be evaluated in isolation from location, process condition, and other relevant observations. Document the actual contribution of each data source to the control strategy and to batch release assessment.

Sources: [1]

3. Link control point, measurement, and decision

Our matrix defines the traceability chain. Depending on the method, information is generated either directly within the measurement system or supplemented after data evaluation. What is essential is that the relationship is preserved. For example, a laboratory result entered manually later must still maintain the correct linkage to the original sample collection.

For a GMP-related computerized system, appropriate Annex 11 principles must also be considered. Assess data transmission, access, modifications, availability, and the required traceability. The validation of an individual component does not automatically demonstrate that the entire chain—including interfaces and technical evaluation—functions correctly.

Own work matrix for the monitoring data chain
TransitionContext neededQuestion to check the control
Control point → Measurement Location, method, and process state Was the measurement taken at the specified point under the correct conditions?
Measurement → Result Probe or measurement, time reference, unit, and evaluation Does the result clearly belong to the original data entry?
Result → Alert Appropriate boundary or trend reference Is the correct rule being applied and the result visible?
Notification → Assessment Responsibility and potential product involvement Who evaluates the effect using which information?
Evaluation → Action Rationale, Implementation, and Conclusion Is the professional judgment independent of the clearance status justifiable?

Sources: [1] [3]

4. Distinguish Alert, Action, and Trend

Annex 1 describes appropriate Alert Levels and Action Limits, as well as trend evaluation. These terms do not simply refer to two arbitrary alarm colors. Upon exceeding Action Limits, procedures shall include a root cause investigation, assessment of potential product impacts, and required corrective or preventive actions.

For alert exceedances, the text outlines an evaluation and traceability process, including consideration of an investigation or corrective actions to prevent further deterioration. Therefore, not every alert notification necessarily requires the same scope of investigation as an action exceedance. However, repetitions, patterns, and altered microbial findings can serve as significant indicators. The specific rule must be clearly defined within the appropriate monitoring procedure.

Sources: [1]

Further reading:

5. Example: Finding with delayed reporting

In this example, a facility takes an environmental sample on Monday at 09:00 hours. Following the planned analysis, a result exceeding the action limit applicable to this scenario is reported on Thursday at 11:00 hours. The period between sample collection and report issuance totals 74 hours: three days equate to 72 hours, plus an additional two hours. This duration is a hypothetical assumption and does not represent a recommended incubation time.

During the period, several batches were manufactured. The investigation must be linked to the relevant manufacturing process and potential product effects. The table presents a standalone intended processing approach. It neither asserts that every batch is automatically affected nor that an alarm clearance constitutes a release decision.

Example: Time and Decision Overview
Time or stepStateRequired assessmentExpected evidence
Monday 09:00 Sample taken at control point K-03 Record the location and associated process status. Unambiguous link to sampling
By Thursday at 11:00 Further manufacturing within the relevant environment Identify potentially affected processes during the period Justified scope of the batches assessed
Thursday 11:00 Action-Finding is reported Investigate root cause and potential product implications Link investigation findings with manufacturing context and additional data
Thursday 11:10 Technical acknowledgement received Acknowledgement indicates awareness as defined by the system. It does not establish that the underlying issue is resolved. Separate status of investigation
Closure Actions and product assessment decided Rationale and efficacy appropriately verifiable Required investigation and actions documented

Sources: [1] [3]

6. Address data gaps and technical failures professionally

A missing transfer is not evidence of undetected conditions. Investigate whether values are present in the measurement system, whether only the transfer is missing, or whether the measurement itself has failed. Such scenarios may require different corrective actions. The technical status should visibly indicate uncertainty, rather than concealing a gap by automatically displaying a green period.

In addition, verify that imported data retains its original temporal and geographical references. The import timestamp must not inadvertently substitute for the actual sample collection time. For critical outages, appropriate alternative methods may be required; the suitability of such methods depends on the method, process, and required reaction time; a general obligation to use a specific device or network is not derived herein.

Sources: [1] [3]

7. Assess modifications to rules and mappings

A modified control point, a new limit configuration, or an updated mapping may alter the interpretation of the data. Review which historical and new results are affected. A simple renaming may be harmless, whereas assigning the same name to a different location may have significant implications.

Annex 1 requires consideration of changes in relation to their impact on the CCS. For the computerized system, appropriate change controls shall be implemented. Document the applicable rules and the date they were in effect, as well as the evidence supporting the new configuration. This ensures that subsequent trend evaluations remain interpretable, rather than combining values from different conditions without a clear contextual framework.

Sources: [1] [3]

8. Checklist for usable monitoring data

The conclusion of an assessment should enable traceability from the original measurement or sampling event through to the business decision. A technical dashboard serves as a supportive tool; its conclusions depend on the underlying data, rules, and responsibilities.

Our checklist focuses on electronic evidence. It does not replace a complete CCS or microbiological assessment. The objective is that these professional judgments are based on sufficiently comprehensive, correctly attributed, and available information.

  • Purpose of monitoring and contribution to CCS identified.
  • Control point, method, and process condition clearly assigned.
  • Reporting and import times are distinguishable from sampling times.
  • Alerts, action, and trend rules appropriately defined.
  • Technical clearance and professional inspection separately traceable.
  • Data gaps and time period until reporting considered.
  • Changes and justified product assessment accompanied by appropriate evidence.

Sources: [1] [3]

Project experience and collaboration

Review the measurement, alarm and assessment together

With production, microbiology, QA and IT, we trace a monitoring event from the measurement point to assessment of an observation. We examine the reading, timing, link to the room or process, and documented response. For a new installation, we agree this sequence before commissioning. For an existing cleanroom process, we first investigate the handovers where problems appear, such as the link from monitoring to deviation management. Your designated experts justify the limits. We help make their implementation and data paths testable.

Frequently asked questions about Monitoring data and data integrity under Annex 1

Do complete monitoring data prove sterility?

No. Annex 1 clearly states that monitoring or testing alone does not provide assurance of sterility. The data support the evaluation of the overall contamination control strategy. Design, procedures, and additional controls must be considered together.

Sources: [1]

Does Annex 1 apply only to sterile products?

Its intended scope is sterile manufacture. A manufacturer may select suitable principles for certain non-sterile areas. In that case it should document which principles it applies and demonstrate their implementation. The whole annex does not automatically apply to every manufacturing process.

Sources: [1]

Is every alert to be treated the same as an action override?

No. Annex 1 distinguishes between the described reactions. Action thresholds require root cause investigation and product impact assessment. Alerts require evaluation and traceability, with appropriate consideration of further investigation or corrective actions. Recurrent alerts may be particularly significant in this context.

Sources: [1]

Does "alarm quitted" mean that the deviation has been closed?

Not automatically. A clearance initially carries the technical or organizational meaning defined within the system. Root cause investigation, product assessment, and corrective actions are separate professional responsibilities. Evidence should clearly indicate the status of each, rather than consolidating all into a single alarm color.

Sources: [1] [3]

Why is the time between measurement and reporting important?

Annex 1 also identifies potential impacts on batches produced between monitoring and reporting periods in cases of action thresholds being exceeded. Therefore, a later available finding may pertain to earlier manufacturing activities. The specific scope must be professionally justified.

Sources: [1]

Are the 74 hours considered the prescribed evaluation period?

No. They apply exclusively to the period from Monday 09:00 to Thursday 11:00 as illustrated in this article. Appropriate methods, evaluation conditions, and reaction pathways must be defined within the specific monitoring program. The calculation does not establish a universal incubation or reporting deadline.

Sources: [1]

Can a transfer gap be considered an inconspicuous period?

Not without clarification. Distinguish between missing transmission and missing measurement. Existing local data may contribute, but must be correctly assigned and evaluated. A gap alone does not provide evidence that the monitored conditions were maintained.

Sources: [1] [3]

Can the import time be used for data received after delivery?

The import time may serve as additional information. It must not inadvertently replace the required original measurement or sampling reference without notice. For professional assessment, it must remain clearly evident when and under what conditions the relevant result was generated.

Sources: [1] [3]

Must a specific sensor type be used?

Annex 1 specifies performance criteria without naming a manufacturer. Under sections 9.16 and 9.17, grade A particle monitoring covers the full critical operation, including setup. It should continuously monitor particles ≥0.5 and ≥5 µm with a suitable sample flow of at least 28 litres per minute. Exceeding an alert level should trigger an alarm. Section 9.24 also calls for continuous viable air monitoring during critical processing, for example with air samplers or settle plates. Assess particular hazards and alternative monitoring strategies against the applicable provisions.

Sources: [1]

How do limit value changes affect trends?

You can alter the interpretation of historical and new data. Ensure that valid rules and their temporal context are traceable. Assess the impact on CCS and system outputs to prevent disparate conditions from appearing as a single, uniform data base.

Sources: [1] [3]

Sources and review date

Source date: 7 October 2026. Regulatory requirements, guidelines, and industry practices must be categorized separately. Tables, figures, and case examples are to be considered standalone reference materials; they do not constitute completed product testing.

  1. EU GMP Annex 1 – Manufacture of Sterile Medicinal ProductsRevision dated 25 August 2022, fully applicable from 25 August 2024. Scope and sections 2.2–2.6 and 9.1–9.13.
  2. European Commission: EudraLex Volume 4Status as of 07.10.2026; Human medicinal products and veterinary law separated.
  3. EU GMP Annex 11 – Computerised SystemsRevision January 2011; listed in the human medicinal product section. Principle, §§1–17.

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Jointly develop the specific evidence process

We support your team in linking electronic monitoring data, technical events, and business decisions to a traceable documentation process.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →